The CRISPR technology market size attained a value of USD 1.8 billion in 2023. By 2032, The market is likely to grow at a rate of 23.1% during the forecast period of 2024-2032 to attain a value of USD 11.9 billion by 2032. The growth can be attributed to the increase in the mergers and acquisitions of trategic key players.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
CRISPR, abbreviated for Clustered Regularly Interspaced Short Palindromic Repeats, refers to prokaryotic DNA elements convoluted in adaptive immunity, identified by groups of similar repeats interspaced with non-identical parts called spacers. CRISPR technology is a dynamic tool used for genome modification in mammalian cells enabling researchers to innovate gene-altered variants of higher quality and lower cost than alternative methods, like transcription activator-like effector nuclease or zinc finger nuclease genome editing.
The protein associated with CRISPR is Cas9 and Cas9 endonuclease is indicated to DNA by a gRNA, which is incorporated as a two-part system made up of trans-activating crRNA and CRISPR RNA or as a sgRNA, wherein the linker connects crRNA and tracrRNA.
Cas9 is incorporated into the CRISPR system, which helps in enabling the rapid expression of genes. This CRISPR Cas9 system also helps in eliminating the risk of inclusion mutagenesis. CRISPR technology is used for the treatment of genetic disorders caused due to the mutation of a single gene and helps eradicate infectious diseases, like HIV.
CRISPR-Cas has evolved from an adaptive immune system to present time's most excellent biotechnology. These ongoing inventions and advancements in this field will drive the growth of the market. According to the CRISPR technology market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Cas Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Companies and investors see the CRISPR-Cas9 technology market as an emerging sector with many foreseen applications in the future. Nonetheless, the passion, endeavours, and financial and industrial firms commend the plausible financial and other societal benefits that are significant.
The first indicators of the market involve firm investments, fees paid for CRISPR license patents, the range of organisations and firms investing in CRISPR research, and primaeval applications. This increase in investments by private and public firms will help provide a better CRISPR technology market outlook.
According to Harvard reports, since 2013, key companies incorporating CRISPR have received over 600 USD million in venture capital and public market investments.
The increased adoption and demand for CRISPR technology are also anticipated to drive the CRISPR technology market expansion. The incorporation of gene editing technologies in different areas, including medicine, biotechnology, and the agricultural sector, is responsible for fuelling the market growth.
The augmentation of genome engineering with possible applications proved to reflect a significant impact on the future of healthcare. The high efficacy of the CRISPR-Cas9 system has been indicated in genome editing studies, which concluded in substantial investments in genome engineering. Nonetheless, many pros and cons also exist, which need cogitation before clinical applications.
Further, many scientists are working on the shortcomings of CRISPR gene editing technology for more effective results. The plausibility of CRISPR gene editing to change the human genome and alter the disease conditions is excellent but exists with moralistic and social affairs. These ethical issues hamper the CRISPR technology market growth.
North America is anticipated to dominate all the regions in the global market. This is due to more product launches, increased awareness, greater expenditure in the healthcare sector and better advancements.
The substantial development in the CRISPR technology market is due to the expanding demand in the food industry for enhanced products with elaborated quality and nutrient embellishment and the pharmaceutical industry for an inclined cure for several diseases.
Furthermore, the significant ongoing investments by healthcare companies and firms to fulfill the industry needs and flourishing eminence for the gene therapy methodologies with lower turnover time are the protrusive aspects propelling the expansion of the market.
Moreover, companies are spending an enormous amount on reformulating and developing CRISPR technology products and gene therapies. The clinical trial outlook of multiple chronic and genetic disorders has increased in the modern era. This will assist in the CRISPR technology market growth and development.
CRISPR technology is mainly utilised in three treatment sectors: cancers, blood disorders, and eye diseases. Other CRISPR applications target other genetic disorders, regenerative medicine, and viral infections.
Easy accessibility for injections into the eyes makes it a potential target for in-vivo genetic engineering, making delivery easier. Some indications in the pipeline for CRISPR technology are Usher Syndrome, Stargardt’s disease, Lever Congenital Amaurosis, and Retinitis Pigmentosa 4. Various researchers are still working on delivering the CRISPR machinery in an AAV vector targeted to photoreceptor cells.
CRISPR technology has been used in cancer to ‘kick in or out’ genes allied to cancer development. In these therapies, immune cells are collected from blood and genetically altered to exhibit tumour-fighting aspects. CRISPR has also been used to develop Chimeric Antigen Receptor T-Cells (CAR-T) therapies for several leukaemia and lymphomas. Genetic engineering of patients’ T-cells ex-vivo is a crucial mechanism in CAR-T therapies.
CRISPR therapies help modify cells and infuse them into the patient for easy delivery. Current CRISPR treatment for blood disorders raises foetal haemoglobin levels, which can replace defective adult haemoglobin. In this therapy, harvested patients’ blood stem cells are genetically engineered by CRISPR to activate the foetal haemoglobin.
Chemotherapy is used to eliminate defective stem cells, and in return, the patient’s body is restored with genome-modified stem cells. After that, these cells create a new blood stem population in bone marrow, which further makes red blood cells with foetal haemoglobin.
CRISPR utilised indications are continuously expanding due to enhancements in the delivery capacity and better knowledge of the genetic basis of diseases. Thus, CRISPR seems promising in treating chronic genetic and autosomal recessive disorders. These developing treatments will help in the CRISPR technology market growth.
Vertex and CRISPR Tx are the first to step forward in treating Duchenne Muscular Dystrophy (DMD). Because of the ease of targeting lipid nanoparticle vectors, liver diseases have also become common targets. CRISPR can also be applicable in the treatment of hepatic disorders.
The advancement of in-vivo delivery will help in utilising CRISPR to treat more complex genetic diseases, which involve hard-to-target monogenic and multigenic disorders. With expanding base development and prime editing, CRISPR will essentially be able to target all types of genetic disorders. This expanding disease genre will help increase CRISPR technology market value.
In the initial period, researchers and scientists mainly worked on reformulating how CRISPR works in different cell types, its efficiency at cutting DNA, and then developing CRISPR for clinical applications. Later, researchers focused on expanding the CRISPR toolbox by discovering and engineering new CRISPR proteins.
The first clinical trials in the field of CRISPR therapeutics begin. The Innovative Genomics Institute (IGI) closely tracks the advancement of novel CRISPR-based therapies and the expansion of clinical trials. Clinical trials have also started subsequently in new disease sectors.
Although the number of CRISPR clinical trials is expanding yearly, most current practices using CRISPR-based treatments are still in the early phases. Thus, the CRISPR-based therapies will require a few years to get proper FDA approval.
The emergence of CRISPR genome technology has opened novel prospects in precision medicine. Clinical trials are undergoing in seven treatment sectors: protein-folding disorders, blood disorders, inflammatory disease, cancers, diabetes, infectious diseases, and inherited eye diseases.
In collaboration with Vertex Pharmaceuticals, CRISPR Therapeutics did a clinical trial for the ex vivo CRISPR-based therapy to treat a genetic disease. According to company press reports, over a year, around 19 more individuals have been treated with the same technique. The results of these trials suggest that patients treated with thalassemia show normal haemoglobin levels, and genome-edited cells were also detected. Vertex Pharmaceuticals and CRISPR Therapeutics are collaboratively working on different trial phases in the United States, Europe, and Canada in the three major countries. This therapy has been given special status in Europe and the United States for fast-track approval.
Beam Therapeutics has also got regulatory approval to move ahead with another Sickle Cell trial to increase foetal haemoglobin.
University of Pennsylvania and Parker Institute tested CAR-T and PD-1 immunotherapy, combined therapies in 2020.
The first CRISPR-based therapy trial consolidated PD-1 and CAR-T immune methods based on CRISPR technology for gene mutation. Researchers concluded that the treatment was safe and had admissible unwanted effects.
All the treatments and therapies are relatively new. Successful results require long-term procedures to supervise the treatment efficacy and to observe the adverse effects. These ongoing clinical trials are emerging as a crucial driver for the CRISPR technology market growth and development.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the CRISPR technology market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Cas Type||
|Breakup by Application||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global CRISPR Technology Market
4.1 Global CRISPR Technology Market Overview
4.2 Global CRISPR Technology Market Analysis
4.2.1 Market Overview
22.214.171.124 Global CRISPR Technology Market Historical Value (2017-2023)
126.96.36.199 Global CRISPR Technology Market Forecast Value (2024-2032)
4.3 Global CRISPR Technology Market by Type
4.3.1 Market Overview
188.8.131.52 Cas9 and gRNA
184.108.40.206 Design Tools
220.127.116.11 Plasmid and Vectors
18.104.22.168 Other Delivery System Products
4.4 Global CRISPR Technology Market by Cas Type
4.4.1 Market Overview
22.214.171.124 Cas3 in Type I Systems
126.96.36.199 Cas9 in Type II Systems
188.8.131.52 Cas10 in Type III Systems
4.5 Global CRISPR Technology Market by Application
4.5.1 Market Overview
184.108.40.206 Genome Engineering
220.127.116.11 Disease Models
18.104.22.168 Functional Genomics
4.6 Global CRISPR Technology Market by End User
4.6.1 Market Overview
22.214.171.124 Academic Research Organisations
126.96.36.199 Biopharmaceutical Companies
188.8.131.52 Agriculture Biotechnology Companies
184.108.40.206 Contract Research Organisations (CROs)
4.7 Global CRISPR Technology Market by Region
4.7.1 Market Overview
220.127.116.11 North America
18.104.22.168.1 Historical Trend (2017-2023)
22.214.171.124.2 Forecast Trend (2024-2032)
126.96.36.199.1 Historical Trend (2017-2023)
188.8.131.52.2 Forecast Trend (2024-2032)
184.108.40.206 Asia Pacific
220.127.116.11.1 Historical Trend (2017-2023)
18.104.22.168.2 Forecast Trend (2024-2032)
22.214.171.124 Latin America
126.96.36.199.1 Historical Trend (2017-2023)
188.8.131.52.2 Forecast Trend (2024-2032)
184.108.40.206 Middle East and Africa
220.127.116.11.1 Historical Trend (2017-2023)
18.104.22.168.2 Forecast Trend (2024-2032)
5 North America CRISPR Technology Market
5.1 United States of America
5.1.1 Historical Trend (2017-2023)
5.1.2 Forecast Trend (2024-2032)
5.2.1 Historical Trend (2017-2023)
5.2.2 Forecast Trend (2024-2032)
6 Europe CRISPR Technology Market
6.1 United Kingdom
6.1.1 Historical Trend (2017-2023)
6.1.2 Forecast Trend (2024-2032)
6.2.1 Historical Trend (2017-2023)
6.2.2 Forecast Trend (2024-2032)
6.3.1 Historical Trend (2017-2023)
6.3.2 Forecast Trend (2024-2032)
6.4.1 Historical Trend (2017-2023)
6.4.2 Forecast Trend (2024-2032)
7 Asia Pacific CRISPR Technology Market
7.1.1 Historical Trend (2017-2023)
7.1.2 Forecast Trend (2024-2032)
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
7.3.1 Historical Trend (2017-2023)
7.3.2 Forecast Trend (2024-2032)
7.4.1 Historical Trend (2017-2023)
7.4.2 Forecast Trend (2024-2032)
7.5.1 Historical Trend (2017-2023)
7.5.2 Forecast Trend (2024-2032)
8 Latin America CRISPR Technology Market
8.1.1 Historical Trend (2017-2023)
8.1.2 Forecast Trend (2024-2032)
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
9 Middle East and Africa CRISPR Technology Market
9.1 Saudi Arabia
9.1.1 Historical Trend (2017-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 United Arab Emirates
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 South Africa
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
10 Trade Data Analysis by HS Code
10.1 Geneart CRISPR Nuclease Mrna- 38220090
10.2 Csq33 DNA Sequencing Unit- 90272000
11 Current Scenario Evaluation and Regulatory Framework
11.1 Emerging Therapies and Clinical Trials Synopsis
11.2 Patent Landscape
11.2.1 Patent Overview
22.214.171.124 Patent Status and Expiry
126.96.36.199 Timelines from Device Development to Commercial Launch
188.8.131.52 New Device Application
184.108.40.206.1 Documentation and Approval Process
11.3 Cost of Treatment
11.4 Regulatory Framework
11.4.1 Regulatory Overview
220.127.116.11 US FDA
18.104.22.168 EU EMA
22.214.171.124 INDIA CDSCO
126.96.36.199 JAPAN PMDA
12 Global CRISPR Technology Market Dynamics
12.1 Market Drivers and Constraints
12.2 SWOT Analysis
12.3 Porter’s Five Forces Model
12.4 Key Demand Indicators
12.5 Key Price Indicators
12.6 Industry Events, Initiatives, and Trends
12.7 Value Chain Analysis
13 Supplier Landscape
13.1 Horizon Discovery Group plc
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.2 Sangamo Therapeutics
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.3 GenScript Biotech
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.4 Integrated DNA Technologies, Inc.
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.5 Precision Biosciences
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.6 Beam Therapeutics Inc.
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.7 Thermo Fisher Scientific Inc.
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.8 Intellia Therapeutics
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.9 CRISPR Therapeutics AG
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.10 Vertex Pharmaceuticals Incorporated
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.11 New England Biolabs
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.12 Agilent Technologies, Inc.
13.12.1 Company Overview
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.13 Merck KGaA
13.13.1 Company Overview
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
14 Recommendations and Discussion
15 Pricing Models and Strategies (Additional Insight)
15.1 Cost Model
15.1.1 Manufacturing Cost Analysis
15.1.2 Procurement Cost Analysis
15.1.3 Clinical Trial Cost Factors
15.2 Pricing Strategies
15.2.1 Competitor Pricing Analysis
15.2.2 Key Assessment of Product Attributes
15.2.3 Pricing Benchmark
16 Global CRISPR Technology Devices Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
The market size is likely to reach a value of USD 1.8 billion in 2023.
The market is likely to grow at a CAGR of 22.43% during the forecast period of 2024-2032 to attain a value of USD 11.9 billion by 2032.
Based on the type, the market is segmented into Cas9 and gRNA, design tools, plasmid and vectors, and other delivery system products.
Based on the Cas type, the market is categorised into Cas3 in Type I systems, Cas9 in Type II systems, and Cas10 in Type III systems.
Based on the application, the market is segmented into genome engineering, disease models, functional genomics, and knockdown/activation, among others.
Based on the end user, the market is categorised into academic research organisations, biopharmaceutical companies, agriculture biotechnology companies, and contract research organisations(CROs).
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The effect of CRISPER-Cas9’s off-target product leads to genomic instability, affecting the market.
The key companies involved in the market are Horizon Discovery Group plc, Sangamo Therapeutics, GenScript Biotech, Integrated DNA Technologies, Inc., Precision Biosciences, Beam Therapeutics Inc., Thermo Fisher Scientific Inc., Intellia Therapeutics, CRISPR Therapeutics AG, Vertex Pharmaceuticals Incorporated, New England Biolabs, Agilent Technologies, Inc., and Merck KGaA, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.